Cepeginferferon alfa-2b (Cepeginterferon alfa-2b)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antiviral drugs (excluding HIV)

Interferons

Included in the formulation
  • Algeron®
    solution PC 
    BIOCAD, CJSC     Russia
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    L.03.A.B   Interferons

    Pharmacodynamics:

    Contains a plasma hybrid that codes for interferon alpha-2b human leukocytes, binds to cellular receptors responsible for inducing enzymes that regulate the processes of transcription of the viral genome. It increases the cytotoxicity of T-lymphocytes and the phagocytic activity of macrophages, thereby enhancing cellular immunity. In addition, it stimulates the production of cytokines.

    Pharmacokinetics:

    After subcutaneous administration, the maximum concentration in the blood plasma is reached after 15-44 hours and is maintained for 48-72 hours.

    Not exposed to metabolism.

    The half-life is 31 hours. Elimination by the kidneys.

    Indications:

    It is used for the treatment of histologically confirmed hepatitis C with monotherapy or in combination with ribavirin.

    ICD-10

    I.B15-B19.B18.2   Chronic viral hepatitis C

    Contraindications:

    Autoimmune processes and mental illnesses (including epilepsy), including in the anamnesis; thyroid dysfunction, severe renal and hepatic insufficiency, individual intolerance, children under 18 years of age.

    Carefully:

    Severe lung diseases, decompensated diabetes mellitus, thrombophlebitis, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Subcutaneously in the thigh or anterior abdominal wall at a dose of 1.5 μg / kg 1 time per week. It is recommended that the injection site be changed every time.

    The highest daily dose: 1.5 mcg / kg.

    The highest single dose: 1.5 mcg / kg.

    Side effects:

    Central and peripheral nervous system: insomnia, headache, impaired concentration, anxiety, depression, hallucinations, convulsive seizures.

    Respiratory system: pharyngitis, cough, shortness of breath.

    Hemopoietic system: anemia, thrombocytopenia, leukopenia, neutropenia.

    The cardiovascular system: tachycardia, arterial hypotension.

    Digestive system: dry mouth, decreased appetite, nausea, diarrhea.

    Musculoskeletal system: arthralgia, myalgia, rhabdomyolysis.

    Dermatological reactions: alopecia.

    Sense organs: conjunctivitis, blurred vision, tinnitus, hearing impairment.

    Urinary system: impaired renal function, renal failure.

    Reproductive system: decreased libido.

    Allergic reactions.

    Overdose:

    Increased dose-dependent effects.

    Treatment is symptomatic.

    Interaction:

    Increases the concentration of theophylline in the blood plasma.

    Special instructions:

    Persons caring for patients taking zheveginterferon alfa-2b should be warned about the possibility of patients appearing suicidal thoughts and attempts.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up